Targeting GM-CSF in rheumatoid arthritis

Clinical and Experimental Rheumatology

Volumn 34, Issue , 2016, Pages 39-44

  Avci, Ali Berkant ^a   Feist, Eugen ^b   Burmester, Gerd Rüdiger ^b  

^a AKDENIZ UNIVERSITY   (Turkey)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

GM CSF; Mavrilimumab; MOR103; Namilumab; Rheumatoid arthritis

Indexed keywords

ADALIMUMAB; C REACTIVE PROTEIN; GOLIMUMAB; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; GSK 3196165; INTERLEUKIN 17; LENZILUMAB; MAVRILIMUMAB; METHOTREXATE; NAMILUMAB; PLACEBO; TUMOR NECROSIS FACTOR; TUMOR NECROSIS FACTOR INHIBITOR; ANTIRHEUMATIC AGENT; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR RECEPTOR; MONOCLONAL ANTIBODY;

ADD ON THERAPY; ALLERGIC REACTION; ARTICLE; BRONCHITIS; CYTOKINE RELEASE; DAS28; DISEASE ACTIVITY; DISEASE EXACERBATION; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ERYTHROCYTE SEDIMENTATION RATE; HUMAN; INFECTION; LUNG ALVEOLUS PROTEINOSIS; MACROPHAGE; MONOCYTOPENIA; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; RESPIRATORY TRACT INFECTION; RHEUMATOID ARTHRITIS; RHINOPHARYNGITIS; ANIMAL; ANTAGONISTS AND INHIBITORS; ARTHRITIS, RHEUMATOID; DRUG EFFECTS; IMMUNOLOGY; METABOLISM; MOLECULARLY TARGETED THERAPY; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; HUMANS; MOLECULAR TARGETED THERAPY; RECEPTORS, GRANULOCYTE-MACROPHAGE COLONY-STIMULATING FACTOR; SIGNAL TRANSDUCTION; TREATMENT OUTCOME;

EID: 84984815851     PISSN: 0392856X     EISSN: 1593098X     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. SMOLEN JS, ALETAHA D: Rheumatoid arthritis therapy reappraisal: strategies, opportunities and challenges. Nat Rev Rheumatol 2015; 11: 276-89.
2. AVCI AB, FEIST E, BURMESTER GR: A Promising Target in Rheumatoid Arthritis Treatment: Granulocyte-Macrophage Colony-Stimulating Factor. Curr Treat Options in Rheum 2015; 1: 320-33.
3. LEIZER T, CEBON J, LAYTON JE, HAMILTON JA: Cytokine regulation of colony-stimulating factor production in cultured human synovial fibroblasts: I. Induction of GM-CSF and G-CSF production by interleukin-1 and tumor necrosis factor. Blood 1990; 76: 1989-96.
4. CAMPBELL IK, NOVAK U, CEBON J, LAYTON JE, HAMILTON JA: Human articular cartilage and chondrocytes produce hemopoietic colony-stimulating factors in culture in response to IL-1. J Immunol 1991; 147: 1238-46.
5. HAMILTON JA: Colony-stimulating factors in inflammation and autoimmunity. Nat Rev Immunol 2008; 8: 533-44.
6. FLEETWOOD AJ, COOK AD, HAMILTON JA: Functions of granulocyte-macrophage colony-stimulating factor. Crit Rev Immunol 2005; 25: 405-28.
7. HANSEN G, HERCUS TR, McCLURE BJ et al.: The structure of the GM-CSF receptor complex reveals a distinct mode of cytokine receptor activation. Cell 2008; 134: 496-507.
8. JENKINS BJ, BLAKE TJ, GONDA TJ: Saturation mutagenesis of the beta subunit of the human granulocyte-macrophage colonystimulating factor receptor shows clustering of constitutive mutations, activation of ERK MAP kinase and STAT pathways, and differential beta subunit tyrosine phosphorylation. Blood 1998; 92: 1989-2002.
9. SATO N, SAKAMAKI K, TERADA N, ARAI K, MIYAJIMA A: Signal transduction by the high-affinity GM-CSF receptor: two distinct cytoplasmic regions of the common beta subunit responsible for different signaling. EMBO J 1993; 12: 4181-9.
10. BROUGHTON SE, NERO TL, DHAGAT U et al.: The betac receptor family -Structural insights and their functional implications. Cytokine 2015; 74: 247-58.
11. HERCUS TR, DHAGAT U, KAN WL et al.: Signalling by the betac family of cytokines. Cytokine Growth Factor Rev 2013; 24: 189-201.
12. HERCUS TR, BARRY EF, DOTTORE M, et al.: High yield production of a soluble human interleukin-3 variant from E. coli with wildtype bioactivity and improved radiolabeling properties. PLoS One 2013; 8: e74376.
13. COOK AD, BRAINE EL, HAMILTON JA: Stimulus-dependent requirement for granulocytemacrophage colony-stimulating factor in inflammation. J Immunol 2004; 173: 4643-51.
14. WICKS IP, ROBERTS AW: Targeting GM-CSF in inflammatory diseases. Nat Rev Rheumatol 2016; 12: 37-48.
15. FLEETWOOD AJ, LAWRENCE T, HAMILTON JA, COOK AD: Granulocyte-macrophage colony-stimulating factor (CSF) and macrophage CSF-dependent macrophage phenotypes display differences in cytokine profiles and transcription factor activities: implications for CSF blockade in inflammation. J Immunol 2007; 178: 5245-52.
16. MANTOVANI A, SOZZANI S, LOCATI M, ALLAVENA P, SICA A: Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 2002; 23: 549-55.
17. CATES AM, HOLDEN VI, MYERS EM, SMITH CK, KAPLAN MJ, KAHLENBERG JM: Interleukin 10 hampers endothelial cell differentiation and enhances the effects of interferon alpha on lupus endothelial cell progenitors. Rheumatology 2015; 54: 1114-23.
18. WILLART MA, DESWARTE K, POULIOT P et al.: Interleukin-1alpha controls allergic sensitization to inhaled house dust mite via the epithelial release of GM-CSF and IL-33. J Exp Med 2012; 209: 1505-17.
19. KRAUSGRUBER T, BLAZEK K, SMALLIE T et al.: IRF5 promotes inflammatory macrophage polarization and TH1-TH17 responses. Nat Immunol 2011; 12: 231-8.
20. SIERRA-FILARDI E, PUIG-KROGER A, BLANCO FJ et al.: Activin A skews macrophage polarization by promoting a proinflammatory phenotype and inhibiting the acquisition of anti-inflammatory macrophage markers. Blood 2011; 117: 5092-101.
21. STANLEY E, LIESCHKE GJ, GRAIL D et al.: Granulocyte/macrophage colony-stimulating factor-deficient mice show no major perturbation of hematopoiesis but develop a characteristic pulmonary pathology. Proc Natl Acad Sci USA 1994; 91: 5592-6.
22. FARAHAT MN, YANNI G, POSTON R, PANAYI GS: Cytokine expression in synovial membranes of patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1993; 52: 870-5.
23. BELL AL, MAGILL MK, McKANE WR, KIRK F, IRVINE AE: Measurement of colony-stimulating factors in synovial fluid: potential clinical value. Rheumatol Int 1995; 14: 177-82.
24. FIELD M, CLINTON L: Expression of GMCSF receptor in rheumatoid arthritis. Lancet 1993; 342: 1244.
25. BERENBAUM F, RAJZBAUM G, AMOR B, TOUBERT A: Evidence for GM-CSF receptor expression in synovial tissue. An analysis by semi-quantitative polymerase chain reaction on rheumatoid arthritis and osteoarthritis synovial biopsies. Eur cytokine Netw 1994; 5: 43-6.
26. MULHERIN D, FITZGERALD O, BRESNIHAN B: Synovial tissue macrophage populations and articular damage in rheumatoid arthritis. Arthritis Rheum 1996; 39: 115-24.
27. HARINGMAN JJ, GERLAG DM, ZWINDERMAN AH et al.: Synovial tissue macrophages: a sensitive biomarker for response to treatment in patients with rheumatoid arthritis. Ann Rheum Dis 2005; 64: 834-8.
28. WIJBRANDTS CA, VERGUNST CE, HARINGMAN JJ, GERLAG DM, SMEETS TJ, TAK PP: Absence of changes in the number of synovial sublining macrophages after ineffective treatment for rheumatoid arthritis: Implications for use of synovial sublining macrophages as a biomarker. Arthritis Rheum 2007; 56: 3869-71.
29. CODARRI L, GYULVESZI G, TOSEVSKI V et al.: RORgammat drives production of the cytokine GM-CSF in helper T cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat Immunol 2011; 12: 560-7.
30. El-BEHI M, CIRIC B, DAI H et al.: The encephalitogenicity of T(H)17 cells is dependent on IL-1-and IL-23-induced production of the cytokine GM-CSF. Nat Immunol 2011; 12: 568-75.
31. COOK AD, BRAINE EL, CAMPBELL IK, RICH MJ, HAMILTON JA: Blockade of collageninduced arthritis post-onset by antibody to granulocyte-macrophage colony-stimulating factor (GM-CSF): requirement for GM-CSF in the effector phase of disease. Arthritis Res 2001; 3: 293-8.
32. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM, HEPP J, BAEUERLE PA, van den BERG WB: GM-CSF neutralisation suppresses inflammation and protects cartilage in acute streptococcal cell wall arthritis of mice. Ann Rheum Dis 2007; 66: 452-7.
33. CAMPBELL IK, BENDELE A, SMITH DA, HAMILTON JA: Granulocyte-macrophage colony stimulating factor exacerbates collagen induced arthritis in mice. Ann Rheum Dis 1997;56: 364-8.
34. LANG RA, METCALF D, CUTHBERTSON RA et al.: Transgenic mice expressing a hemopoietic growth factor gene (GM-CSF) develop accumulations of macrophages, blindness, and a fatal syndrome of tissue damage. Cell 1987; 51: 675-86.
35. CAMPBELL IK, RICH MJ, BISCHOF RJ, DUNN AR, GRAIL D, HAMILTON JA: Protection from collagen-induced arthritis in granulocytemacrophage colony-stimulating factor-deficient mice. J Immunol 1998; 161: 3639-44.
36. HUA F, HENSTOCK PV, TANG B: ERK activation by GM-CSF reduces effectiveness of p38 inhibitor on inhibiting TNFalpha release. Int Immunopharmacol 2010; 10: 730-7.
37. ESPELIN CW, GOLDSIPE A, SORGER PK, LAUFFENBURGER DA, de GRAAF D, HENDRIKS BS: Elevated GM-CSF and IL-1beta levels compromise the ability of p38 MAPK inhibitors to modulate TNFalpha levels in the human monocytic/macrophage U937 cell line. Mol Biosyst 2010; 6: 1956-72.
38. van NIEUWENHUIJZE AE, van de LOO FA, WALGREEN B et al.: Complementary action of granulocyte-macrophage colony-stimulating factor and interleukin-17A induces interleukin-23, receptor activator of nuclear factor-kappaB ligand and matrix metalloproteinases and drives bone and cartilage pathology in experimental arthritis: rationale for combination therapy in rheumatoid arthritis. Arthritis Res Ther 2015; 17: 163.
39. PLATER-ZYBERK C, JOOSTEN LA, HELSEN MM, KOENDERS MI, BAEUERLE PA, van den BERG WB: Combined blockade of granulocyte-macrophage colony stimulating factor and interleukin 17 pathways potently suppresses chronic destructive arthritis in a tumour necrosis factor alpha-independent mouse model. Ann Rheum Dis 2009; 68: 721-8.
40. PEREIRA J, VELLOSO ED, LOTERIO HA, LAURINDO IM, CHAMONE DA: Long-term remission of neutropenia in Felty's syndrome after a short GM-CSF treatment. Acta Haematol 1994; 92: 154-6.
41. HAZENBERG BP, Van LEEUWEN MA, Van RIJSWIJK MH, STERN AC, VELLENGA E: Correction of granulocytopenia in Felty's syndrome by granulocyte-macrophage colonystimulating factor. Simultaneous induction of interleukin-6 release and flare-up of the arthritis. Blood 1989; 74: 2769-70.
42. de VRIES EG, WILLEMSE PH, BIESMA B, STERN AC, LIMBURG PC, VELLENGA E: Flare-up of rheumatoid arthritis during GMCSF treatment after chemotherapy. Lancet 1991; 338: 517-8.
43. BURMESTER GR, FEIST E, SLEEMAN MA, WANG B, WHITE B, MAGRINI F: Mavrilimumab, a human monoclonal antibody targeting GM-CSF receptor-alpha, in subjects with rheumatoid arthritis: a randomised, double-blind, placebo-controlled, phase I, first-in-human study. Ann Rheum Dis 2011; 70: 1542-9.
44. BURMESTER GR, WEINBLATT ME, McINNES IB et al.: Efficacy and safety of mavrilimumab in subjects with rheumatoid arthritis. Ann Rheum Dis 2013; 72: 1445-52.
45. TAKEUCHI T, TANAKA Y, CLOSE D, GODWOOD A, WU CY, SAURIGNY D: Efficacy and safety of mavrilimumab in Japanese subjects with rheumatoid arthritis: findings from a Phase IIa study. Mod Rheumatol 2015; 25: 21-30.
46. BURMESTER GR, McINNES IB, KREMER JM et al.: Efficacy and safety of mavrilimumab, a fully human GM-CSFR-alpha monoclonal antibody in patients with rheumatoid arthritis: primary results from the EARTH EXPLORER 1 study [abstract]. EULAR 2015: Ann Rheum Dis 2015; 74 (Suppl. 2): 78.
47. KREMER JM, BURMESTER GR, WEINBLATT M et al.: Patient-reported outcomes (PROS) during treatment with mavrilimumab, a fully human monoclonal antibody targeting GM-CSFR-alpha, in the phase IIb EARTH EXPLORER 1 study [abstract]. EULAR 2015. Ann Rheum Dis 2015; 74 (Suppl. 2): 483.
48. McINNES IB, BURMESTER GR, KREMER JM et al.: Rapid Onset of Clinical Benefit Is Associated with a Reduction in Validated Biomarkers of Disease in Patients with Rheumatoid Arthritis Treated with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFR [abstract]. ACR 2014.
49. GUO X, SINIBALDI D, KUZIORA M et al.: Sustained response to mavrilimumab in rheumatoid arthritis patients via suppression of macrophage and T cells [abstract]. EULAR 2015. Ann Rheum Dis 2015; 74 (Suppl. 2):734.
50. JIN DC, WU CY, ROSKOS LK, GODWOOD A, CLOSE D, WANG B: Exposure-efficacy analysis of mavrilimumab in rheumatoid arthritis: modeling and simulation of phase II clinical data [abstract]. EULAR 2015. Ann Rheum Dis 2015; 74 (Suppl. 2): 1043.
51. KREMER JM, BURMESTER GR, WEINBLATT M et al.: Analysis of Patient-Reported Outcomes during Treatment with Mavrilimumab, a Human Monoclonal Antibody Targeting GM-CSFRá, in the Randomized Phase 2b Earth Explorer 1 Study [abstract]. ACR 2014.
52. McINNES IB, BURMESTER GR, KREMER JM et al.: Rapid onset of clinical benefit in patients with RA treated with mavrilimumab, a fully human monoclonal antibody targeting GM-CSFR-alpha: subanalysis of the phase IIb EARTH EXPLORER 1 study [abstract]. EULAR 2015. Ann Rheum Dis 2015; 74 (Suppl. 2): 723.
53. A study of Mavrilimumab versus anti tumor necrosis factor in subjects with rheumatoid arthritis. ClinicalTrials.gov [Access date: May 15, 2016]; Available from: https://clinicaltrials. gov/ct2/show/study/NCT01715896
54. BURMESTER GR, McINNES I, KREMER J et al.: Long-term Safety and Efficacy of Mavrilimumab, a Fully Human Granulocyte-Macrophage Colony-Stimulating Factor Receptor-a (GM-CSFR-a) Monoclonal Antibody, in Patients with Rheumatoid Arthritis (RA) [abstract]. ACR 2015. Arthritis Rheumatol 2015; 67 (Suppl. 10).
55. BEHRENS F, TAK PP, OSTERGAARD M et al.: MOR103, a human monoclonal antibody to granulocyte-macrophage colony-stimulating factor, in the treatment of patients with moderate rheumatoid arthritis: results of a phase Ib/IIa randomised, double-blind, placebocontrolled, dose-escalation trial. Ann Rheum Dis 2015; 74: 1058-64.
56. HUIZINGA TWJ, BATALOV A, YABLANSKI K et al.: First-in-patient study of namilumab, an anti-GM-CSF monoclonal antibody, in active rheumatoid arthritis: results of the PRIORA phase Ib study [abstract]. EULAR 2015. Ann Rheum Dis 2015; 74 (Suppl. 2): 733.
57. A Phase 1 MT203 Single-dose Study to Evaluate Safety, PK and PD. ClinicalTrials. gov [Access date: May 15, 2016]; Available from: https://clinicaltrials.gov/ct2/show/ NCT02354599.
58. Dose Finding Study of Namilumab in Combination With Methotrexate in Participants With Moderate to Severe Rheumatoid Arthritis (RA). ClinicalTrials.gov [Access date: May 15, 2016]; Available from: https://clinicaltrials. gov/ct2/show/NCT02379091.
59. Namilumab vs Adalimumab in Participants With Moderate to Severe Early Rheumatoid Arthritis Inadequately Responding to Methotrexate (TELLUS). ClinicalTrials. gov [Access date: May 15, 2016]; Available from: https://clinicaltrials.gov/ct2/show/ NCT02393378.
60. Safety and Tolerability of MORAb-022 in Healthy and Rheumatoid Arthritis Subjects. ClinicalTrials.gov [Access date: May 15, 2016]; Available from: https://clinicaltrials. gov/ct2/results?term=NCT01357759.
61. Study of KB003 In Biologics-Inadequate Rheumatoid Arthritis. ClinicalTrials. gov [Access date: May 15, 2016]; Available from: https://clinicaltrials.gov/ct2/ results?term=NCT00995449.